Rigel Pharmaceuticals has enrolled the first subject in a Phase I trial of its oral spleen tyrosine kinase (SYK) inhibitor, ...

Rigel Pharmaceuticals (NASDAQ:RIGL – Get Free Report)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a note issued to investors on Wednesday,Benzinga reports ...

Research analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Rigel Pharmaceuticals in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst K.

Rigel Pharmaceuticals (RIGL) announced the first patient has been enrolled in a Phase 1 study evaluating the safety and tolerability of ...

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the first patient has been enrolled in a Phase 1 study evaluating ...

Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Rigel (RIGL – Research Report) and keeping the price target at ...

KFDA approves immune thrombocytopenia treatment Tavalisse from Rigel Pharmaceuticals KFDA greenlights Tavalisse, a ...

This article is based on a press release statement from Rigel Pharmaceuticals (NASDAQ:RIGL), Inc. The company maintains a healthy financial position with a current ratio of 1.96 and operates with a ...

Baton, the leading marketplace for small and medium-sized business acquisitions, today announced its Series A raise of $10 million, led by Obvious Ventures with participation from Burst Capital, FJ ...